Physician Search
 |
 |
| Consuelo Wilkins, MD, MSCI, Senior Vice President for Health Equity and Inclusive Excellence for Vanderbilt University Medical Center (VUMC) and Senior Associate Dean for Health Equity and Inclusive Excellence for Vanderbilt University School of Medicine, always knew she wanted to be a physician. "Health equity was built into everything I did, even if I didn’t know it or recognize it at the time," Wilkins said. "I have always learned and believed that people are the same — everyone deserves to be healthy, and everyone should have the best opportunities to take care of themselves and their families." Click below to learn more about health equity initiatives. https://momentum.vicc.org/2021/09/everyone-deserves-to-be-healthy/ |
Vanderbilt was the lead site for an NIH-funded, phase 2, multicenter influenza vaccine study in pediatric allogeneic hematopoietic stem cell transplant (HCT) recipients that may lead to a change in the current flu vaccine recommendations in this vulnerable population. Natasha Halasa, MD, MPH and colleagues recently published in the New England Journal of Medicine, that two doses of high-dose trivalent flu vaccine resulted in higher amounts of influenza-specific antibodies than two doses of standard dose quadrivalent vaccine. https://news.vumc.org/2023/03/02/high-dose-flu-vaccine-beneficial-for-pediatric-stem-cell-transplant-patients/ |
A Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study of VGA039 Following Intravenous or Subcutaneous Administration of Single Ascending Doses in Healthy Adults and
Adult Patients with von Willebrand Disease
Not Available
I
Wheeler, Allison
NCT05776069
NCBH2304-VEGA
REDUCE Post Approval Study - GORE CARDIOFORM Septal Occluder and Antiplatelet Medical Management for Reduction of Recurrent Stroke in Patients with Patent Foramen Ovale (PFO)
Not Available
Piana, Robert
NCT03821129
CRE-ARR0003
Intermediate-Size Population Expanded Access Program (EAP) for Ciltacabtagene Autoleucel (Cilta-Cel) Out-of-Specification (OOS) in Patients with Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
Multiple Myeloma
N/A
Oluwole, Olalekan
NCT05346835
VICC-XDCTT24033
Open-Label Safety Study in Adults and Adolescents with Haemophilia A with and without FVIII Inhibitors Switching Directly from Emicizumab Prophylaxis to NNC0365-3769 (Mim8) Prophylaxis
Not Available
III
Wheeler, Allison
NCT05878938
NCBH2302-FRONTIER5
Identifying Best Approach in Improving Quality of Life and Survival after a Donor Stem Cell Transplant in Older, Medically Infirm, or Frail Patients with Blood Diseases
Hematologic
Hematologic
This phase II/III trial studies the best approach in improving quality of life and survival after a donor stem cell transplant in older, weak, or frail patients with blood diseases. Patients who have undergone a transplant often experience increases in disease and death. One approach, supportive and palliative care (SPC), focuses on relieving symptoms of stress from serious illness and care through physical, cultural, psychological, social, spiritual, and ethical aspects. While a second approach, clinical management of comorbidities (CMC) focuses on managing multiple diseases, other than cancer, such as heart or lung diseases through physical exercise, strength training, stress reduction, medication management, dietary recommendations, and education. Giving SPC, CMC, or a combination of both may work better in improving quality of life and survival after a donor stem cell transplant compared to standard of care in patients with blood diseases.
Hematologic
II/III
Jayani, Reena
NCT03870750
VICC-IDCTT23500
A Study of miRNA 371 in Patients with Germ Cell Tumors
Urologic
Urologic
This trial studies whether the blood marker micro ribonucleic acid (miRNA) 371 can predict the chance of cancer returning in patients with germ cell cancers. Studying samples of blood from patients with germ cell cancers in the laboratory may help doctors predict how likely the cancer will come back.
Urologic
N/A
Rini, Brian
NCT04435756
SWOGUROS1823
Long-term Follow-up Study for Participants of Kite-Sponsored Interventional Studies Treated With Gene-Modified Cells
Multiple Cancer Types
The goal of this clinical study is to learn more about the long-term safety, effectiveness
and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel,
KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored
interventional studies.
and prolonged action of Kite study drugs, axicabtagene ciloleucel, brexucabtagene autoleucel,
KITE-222, KITE-363, KITE-439, KITE-585, and KITE-718, in participants of Kite-sponsored
interventional studies.
Hematologic,
Leukemia,
Lymphoma,
Pediatric Leukemia,
Pediatric Lymphoma
N/A
Kassim, Adetola
NCT05041309
VICCCTT2170
A Combined Biomarker Model for Risk Stratification of Indeterminate Pulmonary Nodules - A Multicenter Prospective Observational Pilot Study
Lung
Lung
This study is being done to evaluate a combined biomarker model for risk stratification of indeterminate pulmonary nodules.
Lung
N/A
Grogan, Eric
NCT06074133
VICC-EDTHO23230
